Dermtech, inc. (CNAC)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Assets
Current assets:
Cash and cash equivalents

67,922

15,374

21,437

15

30

4,753

233

385

449

554

607

744

25

Accounts receivable

1,175

680

814

-

-

580

-

-

-

-

-

-

-

Inventory

75

35

44

-

-

40

-

-

-

-

-

-

-

Prepaid expenses and other current assets

892

1,061

1,399

-

-

26

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

45

51

-

77

67

93

67

97

98

0

Total current assets

70,064

17,150

23,694

61

81

5,399

311

453

543

621

704

843

25

Property and equipment, net

1,736

977

210

-

-

215

-

-

-

-

-

-

-

Other assets

167

84

84

-

-

50

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

0

0

0

169

Cash and marketable securities held in Trust Account

-

-

-

12,432

12,357

-

147,628

146,952

146,350

145,878

145,529

145,178

0

Total assets

71,967

18,211

23,988

12,493

12,439

5,664

147,940

147,405

146,893

146,499

146,234

146,021

194

Liabilities, Convertible Preferred Stock and Stockholders’ Equity
Current liabilities:
Accounts payable

1,561

1,609

1,004

-

-

286

-

-

-

-

-

-

-

Accrued compensation

1,120

1,142

1,099

-

-

480

-

-

-

-

-

-

-

Accrued liabilities

200

218

171

-

-

286

-

-

-

-

-

-

-

Deferred revenue

1,093

1,390

1,457

-

-

1,552

-

-

-

-

-

-

-

Deferred underwriting fees

1,363

1,363

1,363

-

-

-

-

-

-

-

-

-

-

Convertible notes payable, net

-

-

-

-

-

5,019

-

-

-

-

-

-

-

Derivative liability

-

-

-

-

-

2,880

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

2,353

1,522

-

631

98

30

27

13

53

4

Advances and notes payable

-

-

-

116

36

-

-

-

-

-

-

-

-

Advances from related parties

-

-

-

-

-

-

11

11

11

11

11

4

168

Total current liabilities

-

-

5,094

2,469

1,558

10,503

642

109

41

38

24

58

172

Notes payable, noncurrent

-

-

-

-

-

516

-

-

-

-

-

-

-

Deferred underwriting fees

-

-

-

4,312

5,031

-

5,031

5,031

5,031

5,031

5,031

5,031

0

Total current and total liabilities

5,337

5,722

5,094

6,781

6,589

11,019

5,674

5,140

5,073

5,069

5,055

5,089

172

Commitments and contingencies

-

-

-

-

-

-

0

0

-

0

0

0

0

Convertible preferred stock

-

-

-

0

0

-

0

0

0

0

0

0

0

Ordinary shares subject to possible redemption, 67,956 and 81,701 shares at redemption values as of June 30, 2019 and March 31, 2019, respectively

-

-

-

711

850

-

137,266

137,264

136,820

136,430

136,178

135,932

0

Stockholders’ equity:
Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 14,899,701 and 12,344,818 shares issued and outstanding at March 31, 2020 and December 31, 2019

1

1

1

3,340

3,201

1

3,700

3,702

4,146

4,536

4,788

5,034

25

Additional paid-in capital

164,741

103,599

104,889

-

-

66,021

-

-

-

-

-

-

-

Accumulated deficit

-98,112

-91,111

-85,996

1,659

1,798

-71,377

1,299

1,297

853

463

211

-34

-2

Total stockholders’ equity

66,630

12,489

18,894

5,000

5,000

-5,355

5,000

5,000

5,000

5,000

5,000

5,000

22

Total liabilities, convertible preferred stock and stockholders’ equity

71,967

18,211

23,988

12,493

12,439

5,664

147,940

147,405

146,893

146,499

146,234

146,021

194